The results of meconium specimens and fortified samples screened for drugs of abuse by both enzyme-linked immunosorbent assay (ELISA, Immunalysis) and biochip microarray (Randox) methods were compared. The ELISA method was semi-automated using a TECAN Genesis. The Randox assay used the Randox Evidence Investigator system. Previously validated gas chromatographymass spectrometry (GC-MS), GC-GC-MS, or liquid chromatography-MS-MS methods were used for confirmation and quantitation. Results from the two techniques compared well. Agreement of the Randox assay was greater than 90% when compared to the ELISA assay for all drug classes except cannabinoids (88%). Specificity of the biochip assay was slightly better for amphetamines and cocaine.
Introduction
According to the SAMHSA National Survey on Drug Use and Health Report from September 2008, 5.2% of all pregnant women surveyed aged 15-44 admitted to using illicit drugs in the past month. The number was 22.6% for pregnant women aged 15-17 years (1) . Early detection of in utero drug exposure is critical for effective management of withdrawal symptoms, proper treatment, and improved long-term outcomes (2) . Results are also used in child-custody proceedings if removal from the home is in the best interest of the child. Although fetal urine, blood, hair, and more recently, umbilical cord and placental tissue have been used to test for drugs of abuse, meconium remains the specimen of choice for determination of prenatal drug exposure. Collection of urine and blood from newborns can be logistically difficult, invasive, and have a very short detection window (typically a few days before birth). Collection of hair can be met with opposition, and often very little hair is present. In addition, incorporation of drugs into hair can vary by hair color or type, and accurate detection can be compromised by external contamination or cosmetic treatments (3) . Umbilical cord and placental tissue have only been recently studied, and few validated methods have been published (4) (5) (6) (7) . Also, drug concentrations in cord tissue are generally lower than in meconium. Meconium is the black, tarry stool passed by the newborn for the first 1-5 days after birth (8) . It begins to form in the digestive tract between 12 and 16 weeks gestation and accumulates until birth. Drugs and their metabolites collect in meconium beginning at approximately 5 months gestation, and at term it can effectively identify exposure during the last trimester of pregnancy (9) (10) (11) . Meconium is a very complex specimen matrix (12) , and consequently, the incidence of matrix interferences is greatly increased in meconium specimens when compared to urine specimens. This complexity can create challenges when developing drug screening methods. Immunoassay techniques developed for urine or blood have been used successfully to detect drugs of abuse in meconium (13) . An enzyme-linked immunosorbent assay (ELISA, Immunalysis, Pomona, CA) and an automated diluter/pipettor (TECAN Genesis, Männedorf, Switzerland) were used in this study for screening of meconium specimens, but the desire for full automation, and better specificity resulted in evaluation of the Randox DOA I Biochip (Crumlin, U.K.) for screening of meconium specimens. The Randox biochip is a competitive ELISA-based assay where antibody for specific drugs are immobilized on discrete regions of a 2-mm × 2-mm biochip. Enzyme conjugate was added, and after incubation, the chips were washed, then a chemiluminescent signal reagent was added. The signal from prepared and extracted patient specimens were compared to the signal from a ninepoint calibration curve. Each biochip can accommodated up to 20 different tests. This allows for multiplexing of samples. The ELISA assay requires at least nine 96-well plates (one for each drug class).
from Cerilliant (Austin, TX). All solvents were reagent grade or better and purchased from Thermo-Fisher Scientific (Waltham, MA) or VWR (West Chester, PA). Type I water was generated using a Barnstead Nanopure Infinity ultra pure water system (Thermo Fisher Scientific, Waltham, MA). Extraction buffer and analysis kits for the ELISA assay were purchased from Immunalysis. Instrumentation and analysis kits for the biochip assay were supplied by Randox. Drugfree meconium was pooled from excess patient specimens that tested negative by ELISA and confirmed to be free of drugs of abuse by gas chromatography-mass spectrometry (GC-MS), liquid chromatography-tandem mass spectrometry (LC-MS-MS), or two-dimensional gas chromatography mass spectrometry (GC-GC-MS). This drug-free meconium was used to prepare calibrators, controls, and fortified samples. Positive patient specimens were obtained from residual patient specimens that confirmed positive and were deidentified to protect personal health information according to the University of Utah's IRB (Institutional Review Board) protocol.
The drugs used for calibration, the published ELISA and biochip cutoff concentrations, the validated confirmation cutoffs, and the technique used for confirmation are summarized in Table I by drug class. Nine assays were performed using both techniques. Calibrators prepared in duplicate with drug-free meconium were fortified at the cutoff concentration for each drug class, and the average value was used to determine positivity for the ELISA assay. A nine-point calibration curve created with calibrators supplied with the biochip kits was used for the biochip assay. Negative and positive controls were prepared using drug-free meconium fortified at zero, 50% (negative controls), and 150% (positive control) of the cutoff concentration and evaluated using both assays. These were prepared, extracted, and analyzed with each batch of samples to assure adequate assay performance. Meconium samples were fortified with solutions prepared from purchased stocks that were diluted to the appropriate concentration in methanol. Different lots of standards were used to prepare calibrators and controls.
Apparatus
Homogenation of the meconium specimens was performed using a sonicator. Dilution and pipetting of the ELISA samples was done using a TECAN Genesis 150 equipped with 5-mL polypropylene tubes and 96-well microtiter plates. ELISA plates were washed using a Columbus 16-well plate washer (TECAN, Männedorf, Switzerland), and read using a TECAN Sunrise plate reader. The biochip samples were analyzed using the Randox DOA I biochip designed for whole blood packaged in carriers containing nine biochips. A six carrier rack (for a total of 54 chips), a thermoshaker, and the Evidence Investigator (for signal detection) all supplied by Randox were also used. The first rack of nine biochips was always used for the nine calibrators supplied with the Randox kits. These calibrators were prepared and analyzed according to the kit instructions. Meconium specimens were prepared and analyzed using a modified procedure described later.
Methods

Sample preparation and analysis by ELISA
First, 0.25 g of each meconium specimen was weighed into 5-mL polypropylene transfer tubes, followed by the addition of 2 mL of Immunalysis N-EXT extraction buffer. The tubes were vortex mixed for 30 s, and then sonicated for 30 min. The samples were then centrifuged at 14,000 rpm and 0°C for 15 min. The supernatant was collected and poured into 5-mL polypropylene tubes. Calibrators and controls were prepared by fortifying 0.25-g aliquots of drug-free meconium at the appropriate concentration using stock solutions prepared in methanol. The ELISA extracts, calibrators, and controls were loaded onto the TECAN Genesis. Two-hundred microliters of each sample was pipetted into individual 5-mL polypropylene tubes. Each 200-µL sample was diluted with 800 µL of phosphate buffered saline. After dilution, an aliquot of each diluted sample was pipetted into a well of each 96-well microtiter plate, one 96-well plate for each drug class (nine drug classes and microtiter plates total). The amount of sample added per well for each drug class was optimized with assistance from Immunalysis. The TECAN Genesis added 100 µL of enzyme conjugate (specific to each drug class) to each well, and the plates were incubated at room temperature for 1 h. The plates were removed, the conjugate was aspirated, and each plate was washed 6 times with deionized water using a Columbus 16-well plate washer. The plates were placed back on the TECAN Genesis, and 100 µL of 3,3',5,5'-tetramethylbenzidrine (TMB) substrate was added to each well. The samples were incubated for 30 min at room temperature. Next, the TECAN Genesis added 100 µL of stop solution (1 N HCl) to each well. The plates were removed from the TECAN Genesis and the plates were read using a TECAN Sunrise plate reader at 450 nm.
Sample preparation and analysis using biochip assay Nine calibrators provided with the Randox kits were prepared and analyzed with each batch of samples following the kit instructions. First, 0.25 g of each meconium specimen was weighed into 5-mL polypropylene transfer tubes, followed by addition of 2 mL of phosphate buffered saline (PBS) with 0.1% Triton X-100. The tubes were vortex mixed for 30 s and then sonicated for 30 min. The samples were then centrifuged at 14,000 rpm and 0°C for 15 min. The supernatant was collected and poured into 5-mL polypropylene tubes. One-hundredtwenty microliters of Randox assay buffer and 60 µL of meconium extract were pipetted into individual Randox DOA I biochips containing antibody for 10 drug classes: amphetamine, methamphetamine, barbiturates (phenobarbital), benzodiazepines I (oxazepam), benzodiazepine II (lorazepam), benzoylecgonine, opioids (morphine), methadone, PCP, and 9-carboxy-11-nor-∆ 9 -THC. One-hundred-twenty microliters of conjugate was added to each chip, and the entire rack of chips (6 9-chip carriers, including 9 calibrators and 48 extracted fortified samples or specimens, 54 samples total) was placed on the thermoshaker for 30 min at 330 rpm and 25°C. The chip carrier was removed from the thermoshaker and rinsed six times with Randox wash buffer. Next, the signal reagent was mixed following the kit instructions, and 250 µL was added to the chips nine at a time (one carrier at a time). Each carrier was incubated for 2 min protected from light, then placed in the Evidence Investigator to read the signal. Signal from the sample chips was compared to the signal produced by the calibrators to obtain a semiquantitative result.
Method comparison
The 2 methods were compared by analyzing 75 patient specimens and drug-free meconium fortified at 8 concentrations between 25 and 200% of the cutoff for each drug class: a negative (0%) control was also included. Specimens that screened positive by ELISA were confirmed by GC-MS, LC-MS-MS, or GC-GC-MS. Samples that screened positive using the biochip assay but were negative by ELISA were not confirmed because there was an insufficient quantity of residual patient specimen (quantity not sufficient or QNS). Most of the specimens screened positive for more than one drug class and also confirmed positive for multiple analytes within a drug class, so the total number of confirmed positive results was 233 using both assays.
Results and Discussion
Fortified samples Drug-free meconium fortified at concentrations between 25% and 200% of the ELISA cutoff concentration were prepared and analyzed by both methods. The ELISA response data is shown in Figure 1 as the fortified concentration versus b/b 0 . This is called the percent binding value. The b/b 0 is a normalized value calculated by dividing the optical density (OD) of the fortified sample by the OD of the 0% control (blank) and expressed as a percent. The b/b 0 value ideally should be between 40 and 60% at the ELISA cutoff. The biochip data are shown in Figure 2 as the fortified concentrations versus the concentrations calculated using the kit calibrators. A linear correlation between the actual fortified concentrations and the calculated concentrations was observed for the biochip assay; however, the concentrations did not agree. This is because the DOA I biochip was designed for whole blood, and the sample preparation for meconium differed from the procedure for whole blood. The result was that the actual concentration applied to the biochip using the extracted meconium specimens was not the same as it would have been if they were whole blood specimens. Even though there was not a 1:1 correlation between the concentrations determined using the Randox calibrators and the actual concentrations, the apparent concentration at the cutoff is known, and hence the method can reliably distinguish between positive and negative specimens.
Patient specimen comparison
Table II details the number of confirmed positives, the concentration range, and the cross-reactivity for each analyte for both techniques. Overall, there was a total of 13 false-positive results for the ELISA assay and nine for the biochip assay. There were three false negatives for each assay.
Ten patient specimens screened positive by biochip, but were negative by ELISA. Detailed results summarized by drug class follow. All cross-reactivity data were provided by the manufacturers (14,15). All methods used for confirmation of results were validated for clinical use and met CAP, CLIA, and New York Department of Health assay performance requirements.
Cannabinoids (9-carboxy-11-nor-∆ 9 -THC)
The ELISA assay detected a total of 26 confirmed positive specimens for 9-carboxy-11-nor-∆ 9 -THC, the biochip assay detected only 23. The three specimens that were not detected by the biochip assay had concentrations of 16, 29, and 30 ng/g, which are all near the cutoff of 20 ng/g. The biochip assay also detected two specimens that did not screen positive by ELISA, but these results were not confirmed. Results were confirmed by GC-GC-MS (16) .
Amphetamine
The ELISA assay detected 17 confirmed positive patient specimens for amphetamine, the biochip assay detected 19. Because these two discrepant specimens were also positive for methamphetamine, and amphetamine and methamphetamine are both included in our GC-MS confirmation assay, these two specimens were confirmed positive for amphetamine, one at 27 ng/g and one at 31 ng/g. Both specimens also contained methamphetamine. The biochip assay also detected one specimen that was not detected by ELISA; however, the specimen was QNS to confirm.
Methamphetamine
The ELISA assay detected 17 confirmed positive specimens for methamphetamine, and the biochip assay detected 18. Although there is a linear correlation, because of sample preparation differences for meconium and matrix effects, the expected and actual conentrations do not agree.
As described previously, because amphetamine and methamphetamine are in the same confirmation assay and the specimen in question was also positive for amphetamine, the positive methamphetamine result using the biochip assay was confirmed (4739 ng/g). One specimen that screened positive by both methods had no amphetamine or methamphetamine but was confirmed to have MDA at 167 ng/g and MDMA at 2001 ng/g (these analytes are also included in our confirmation assay). Cross-reactivity for MDA is 250% by ELISA and 426% with the biochip antibody. Cross-reactivity with MDMA is 136% for the ELISA antibody and 42.5% with the biochip. The biochip assay also detected two specimens that were not detected by ELISA; however, these specimens were QNS to confirm.
Methadone
The ELISA assay and the biochip assay both detected 16 confirmed positive specimens for methadone. These results were confirmed by LC-MS-MS.
Cocaine metabolite (benzoylecgonine)
Both assays correctly detected 26 confirmed-positive specimens for benzoylecgonine (Be). One of the specimens also contained cocaethylene, 9 confirmed positive for cocaine, and 22 had m-OH-benzoylecgonine. There were eight specimens that incorrectly screened positive for Be by ELISA, and there were five false positives with the biochip assay. These results were confirmed by GC-MS.
Phencyclidine (PCP)
Both assays correctly indentified two positive specimens for PCP. These were confirmed by GC-MS.
Barbiturates
The ELISA assay has an antibody designed to cross-react at 100% with secobarbital, and the biochip assay uses an antibody that cross-reacts at 100% with phenobarbital. Both assays detected six positive specimens for barbiturates, and each assay had one false-positive result. Results were confirmed by GC-MS. The biochip assay also detected one specimen that was not detected by ELISA; however, the specimen was QNS to confirm.
Benzodiazepines
The ELISA assay uses an antibody that cross-reacts at 100% with oxazepam, but clonazepam was used as the calibrator (13, 17) . The biochip assay has two benzodiazepine assays: one that is maximized for detection of oxazepam and one for lorazepam. If the biochip assay results are combined, both techniques detected 13 confirmed positive specimens for benzodiazepines. Each method had two false-positive results but no false-negative results. Results were confirmed by LC-MS-MS (18). 
Opioids
Both opioid assays use morphine as the calibrator, but the calibrator in the ELISA assay was changed to hydrocodone to maximize cross-reactivity for this drug (13) . Both methods detected 32 positive specimens and 2 false-positive results, which were confirmed by LC-MS-MS (19) . The biochip assay also detected one specimen that was not detected by ELISA; however, the specimen was QNS to confirm.
Summary
Results from the two techniques compared well. Accuracy of the biochip assay was greater than 90% for all drug classes except for THC when compared to ELISA. ELISA detected more positive specimens for THC. This could be due to the N-EXT extraction buffer having a better ability to extract 9-carboxy-11-nor-∆ 9 -THC from meconium than the PBS with Triton X-100. The N-EXT buffer is a proprietary formulation. The Randox assay detected fewer false-positive results for benzoylecgonine, two fewer false positives for amphetamine, and one fewer false positive for methamphetamine.
Conclusions
The Randox DOA I biochip can be used to screen meconium specimens for drugs of abuse. The Randox assay had comparable cutoffs for all drug classes except methamphetamine (20 ng/g for ELISA versus 100 ng/g for the biochip assay). The ELISA assay appeared to have better sensitivity for cannabinoids, but this could be due to better extraction efficiency. The ELISA assay also had slightly better specificity for amphetamine and methamphetamine. The Randox assay had better specificity for benzoylecgonine.
